Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)
COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Anders Bjartell
Malmo, Skåne County, Sweden
Ryhovs Hospital
Jönköping, Småland, Sweden
Sahlgrenska University Hospital
Gothenburg, Sweden
Linköping University Hospital
Linköping, Sweden
Sundsvall Region Hosptial
Sundsvall, Sweden
Umeå Univerisity Hospital
Umeå, Sweden
Start Date
July 15, 2020
Primary Completion Date
March 24, 2021
Completion Date
May 29, 2021
Last Updated
June 2, 2022
42
ACTUAL participants
Enzalutamide Pill
DRUG
Lead Sponsor
Andreas Josefsson
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06631287